References
- Statistics Canada. New cases and 1991 age-standardized rate for primary cancer (based on the August 2015 CCR tabulation file), by cancer type and sex, Canada, provinces and territories, CANSIM (Table 103-0553). Ottawa: Statistics Canada. Available at: http://www5.statcan.gc.ca/cansim/a05?lang=eng&id=1030553 [last accessed on May 2017]
- American Cancer Society. What are the key statistics about acute lymphocytic leukemia? Indianapolis: American Cancer Society; 2016. Available at: http://www.cancer.org/cancer/leukemia-acutelymphocyticallinadults/detailedguide/leukemia-acute-lymphocytic-key-statistics
- Canadian Cancer Society. What is acute lymphocytic leukemia? Toronto: Canadian Cancer Society; 2016. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-acute-lymphocytic-all/acute-lymphocytic-leukemia/
- Thomas DA, O’Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2009;113:6330-7
- Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med 2016;375:1044-53
- Pui CH, Pei D, Campana D, et al. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 2014;28:2336-43
- Rubnitz JE, Inaba H, Leung WH, et al. Definition of cure in childhood acute myeloid leukemia. Cancer 2014;120:2490-6
- pan-Canadian Drug Oncology Review. Final economic guidance report: blinatumomab (blincyto) for acute lymphoblastic leukemia. Ottawa: pCODR; 2016
- Cancer Care Manitoba. 2016-16 Annual Report. Winnipeg: Cancer Care Manitoba; 2016. Available at: http://www.cancercarefdn.mb.ca/wp-content/uploads/2016/08/CCF-6213-201516-Annual-Report_online.pdf
- Cancer Care Ontario. HYPERCVAD; HYPERCVAD + RITU. Toronto: CCO; 2015
- DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 2015;29:526-34.
- Cancer Research UK. Acute lymphoblastic leukaemia (C91.0): 2011–2013. Average number of new cases per year and age-specific icidence rates per 100,000 population, UK. London: Cancer Research UK; 2016. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-all/incidence#heading-One
- Paulson K, Szwajcer D, Raymond CB, et al. The role of hematopoietic cell transplantation in adult ALL: clinical equipoise persists. Leuk Res 2014;38:176-9
- Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 4th Edition. Ottawa: CADTH; 2017
- Guyot P, Ades A, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Method 2012;12:1-13
- Statistics Canada. Life tables, Canada, provinces and territories 2009 to 2011 (84-537-X). Ottawa: Statistics Canada; 2013
- Martin PJ, Counts GW, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010;28:1011-16
- Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589-96
- Huntsman Cancer Institute. A review of advances in benign and malignant hematology. Huntsman Cancer Institute Sixth Annual Hematology Review. Salt Lake City: Huntsman Cancer Institute; 2016
- Burgden S. Chemotherapy waste: implications for value in health. CADTH Symposium; April 17, 2012; Ottawa, Canada; 2012
- Quintiles IMS. Integrated market access console – DeltaPA. Durham: Quintiles IMS; 2016. Available at: https://customerportal.imshealth.com/portal/site/imsportal
- Tam VC, Ko YJ, Mittmann N, et al. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol (Toronto, Ont) 2013;20:e90-e106
- Ministry of Health and Long-Term Care. Schedule of benefits physician services under the health insurance act. Toronto: MOHLTC; 2016
- Ministry of Health and Long-Term Care. Schedule of benefits for laboratory services. Toronto: MOHLTC; 1999
- Zaric GS, Brennan AW, Varenbut M, et al. The cost of providing methadone maintenance treatment in Ontario, Canada. Am J Drug Alcohol Abuse 2012;38:559-66
- Ministry of Health and Long-Term Care. Ontario case costing cost analysis tool. Toronto: MOHLTC; 2017. Available at: https://hsimi.on.ca/hdbportal/
- Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57-66
- Aristides M, Barlev A, Barber B, et al. Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom. Health Quality Life Outcomes 2015;13:1-7
- Matza LS, Cong Z, Chung K, et al. Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Prefer Adher 2013;7:855-65
- Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663-71
- Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 2003;101:3809-17
- Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-45
- Schrappe M, Zimmermann M, Möricke A, et al. Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 patients (Trial AIEOP-BFM ALL 2000). Blood 2008;112:7
- Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children9s Oncology Group. Blood 2008;111:2548-55
- Larsen E, Salzer W, Devidas M, et al. Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): a report from the Children’s Oncology Group Study AALL0232. J Clin Oncol 2011;29(18suppl):3
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6
- Cancer Care Ontario. Systemic treatment funding model: resource intensity weights/workloads for evidence-informed regimens. Toronto: Cancer Care Ontario; 2016. Available at: https://www.cancercare.on.ca/toolbox/drugformulary/stfmregimens/
- Ministry of Health and Long-Term Care. Ontario case costing initiative. Toronto: MOHLTC; 2016. Available at: https://hsimi.on.ca/hdbportal/